Combination Strategies to Improve Targeted Radionuclide Therapy

Chan, Tiffany G.; O’Neill, Edward; Habjan, Christine; Cornelissen, Bart

doi:10.2967/jnumed.120.248062

Cited by 50 publications

(29 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2,10,11,13,16,20,92,102,135,245,262). In studies on non-CNS tumors, PRRT has been successful both when used alone (4,11,20,21,42,73,74) and in combination with other cytotoxic therapies, including chemotherapy (284,(305)(306)(307)(308)(309). Third, the BnR ectopic expression/overexpression by these tumors can be used also for targeted delivery of cytotoxic non-radiolabeled compounds including chemotherapeutic agents, which is increasingly being studied in other malignant tumors (4,10,13,42,74,78,79).…”

Section: Discussion/conclusionmentioning

confidence: 99%

Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy

et al. 2021

View full text Add to dashboard Cite

G-protein-coupled receptors (GPCRs) are increasingly being considered as possible therapeutic targets in cancers. Activation of GPCR on tumors can have prominent growth effects, and GPCRs are frequently over-/ectopically expressed on tumors and thus can be used for targeted therapy. CNS/neural tumors are receiving increasing attention using this approach. Gliomas are the most frequent primary malignant brain/CNS tumor with glioblastoma having a 10-year survival <1%; neuroblastomas are the most common extracranial solid tumor in children with long-term survival<40%, and medulloblastomas are less common, but one subgroup has a 5-year survival <60%. Thus, there is an increased need for more effective treatments of these tumors. The Bombesin-receptor family (BnRs) is one of the GPCRs that are most frequently over/ectopically expressed by common tumors and is receiving particular attention as a possible therapeutic target in several tumors, particularly in prostate, breast, and lung cancer. We review in this paper evidence suggesting why a similar approach in some CNS/neural tumors (gliomas, neuroblastomas, medulloblastomas) should also be considered.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A few other approaches were also evolved in recent times. The development of drug mimetics where a drug-like molecule can thwart the cancer-inducing effects of mutated regulator proteins [153,154], targeted radionuclide therapy (TRNT) where the radionuclides can potentially destroy tumor cells even if they do not possess specific tumor-associated antigen or receptor or biomarkers [155,156], bacterial cancer therapy where magnetically responsive bacteria are directed to tumor sites where they secrete toxins and compete for nutrients with the tumor cells thus destroying the tumor cells by modulating immune responses [157], multi-ion radiotherapy where a pure beam of heavy ions (like carbon ion) is used for radiotherapy [158], etc. are some of the other recent developments being explored for potential therapeutic uses in cancer cure.…”

Section: Other Approachesmentioning

confidence: 99%

Nanoparticles in Clinical Translation for Cancer Therapy

Mundekkad

Cho

2022

IJMS

150

View full text Add to dashboard Cite

The advent of cancer therapeutics brought a paradigm shift from conventional therapy to precision medicine. The new therapeutic modalities accomplished through the properties of nanomaterials have extended their scope in cancer therapy beyond conventional drug delivery. Nanoparticles can be channeled in cancer therapy to encapsulate active pharmaceutical ingredients and deliver them to the tumor site in a more efficient manner. This review enumerates various types of nanoparticles that have entered clinical trials for cancer treatment. The obstacles in the journey of nanodrug from clinic to market are also reviewed. Furthermore, the latest developments in using nanoparticles in cancer therapy are also highlighted.

show abstract

“…Around 20% of patients treated with 225 Ac-PSMA-617 have a poor response (Table 5) or early resistance against 225 Ac-PSMA-617 [107], despite sufficient expression of PSMA and uptake of 225 Ac-PSMA-617 in their tumors [192]. Several combination treatments with PSMA-TAT have been proposed [173,192,193]. Their goal is to increase PSMA-TAT efficacy by using therapies with different action mechanisms together with TAT, keeping toxic effects to a minimum.…”

Section: Combination Treatments With Psma-tatmentioning

confidence: 99%

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer

Juzeniene

Stenberg

Bruland

et al. 2021

Cancers

View full text Add to dashboard Cite

Bone, lymph node, and visceral metastases are frequent in castrate-resistant prostate cancer patients. Since such patients have only a few months’ survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β- therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT.

show abstract

Combination Strategies to Improve Targeted Radionuclide Therapy

Cited by 50 publications

References 92 publications

Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy

Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy

Nanoparticles in Clinical Translation for Cancer Therapy

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About